Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C: a retrospective clinical study
BACKGROUND: Treatment of chronic hepatitis C (CHC) with pegylated interferon-alpha/ribavirin is associated with wellcharacterized dermatological adverse events (AEs),which can lead to premature discontinuation of treatment.AIMS: To investigate the incidence and spectrum of dermatological AEs during CHC treatment with interferon-alpha plus ribavirin and analyzed factors predisposing patients to such reactions.METHODS: Between January 2008 and December 2012,152 CHC patients who had received intefferon/pegylated interferon plus ribavirin therapy were enrolled in this retrospective study.To determine which factors were associated with dermatological AE development,a Cox proportional-hazards regression analysis was performed.RESULTS: Thirty dermatological AEs were recorded in 28 (18.4%) patients.These reactions included 14 (9.2%) patients with eczematous reactions,four (2.6%) patients with xerosis,three (2.0%) patients with new-onset or exacerbation of psoriasis,two (1.3%) patients with lichenoid eruption,two (1.3%) patients with diffuse folliculitis and one patient with lichen planus,alopecia areata,hypermelanosis,and necrosis of the skin and toenails.Application of the Cox proportional-hazards model revealed that age (HR=1.070;95% CI: 1.043-1.096),pre-existing anaphylaxis/skin disease (HR=2.612;95% CI: 1.593-3.324),cirrhosis (HR=1.863;95% CI: 1.047-3.013),and treatment with pegylated interferon formulations (HR=1.930;95% CI: 1.052-3.687) were associated with occurrence of dermatologic AEs.Twenty-seven (90%) skin conditions were classified as mild to moderate,while one case (3.3%) warranted premature discontinuation of treatment.CONCLUSIONS: Dermatological AEs resulting from interferon-alpha/ribavirin treatment of CHC contribute to a wide spectrurn involve the skin,mucous membrane,nails,and hair.These dermatological AEs correlated with patient age,previous skin condition,cirrhosis,and use of pegylated interferon formulations.
adverse skin reactions chronic hepatitis C pegylated interferon alpha 2b
Fanpu Ji Zhengxiao Li Zhifang Cai Hongan Xue Xiaoli Jia Yanfei Zhang Jingang An Hong Deng
Department of Infectious Diseases,the second affiliated hospital,college of medicine,Xi”an Jiaotong Department of Dermatology,the second affiliated hospital,college of medicine,Xi”an Jiaotong Universi
国内会议
成都
英文
173-181
2014-08-14（万方平台首次上网日期，不代表论文的发表时间）